Search

Your search keyword '"Peters Oliver"' showing total 18 results
Start Over Author "Peters Oliver" Publisher biomed central
18 results on '"Peters Oliver"'

3. A proteomics analysis of 5xFAD mouse brain regions reveals the lysosome-associated protein Arl8b as a candidate biomarker for Alzheimer’s disease

Author

Boeddrich, Annett, Haenig, Christian, Neuendorf, Nancy, Blanc, Eric, Ivanov, Andranik, Kirchner, Marieluise, Schleumann, Philipp, Bayraktaroğlu, Irem, Richter, Matthias, Molenda, Christine Mirjam, Sporbert, Anje, Zenkner, Martina, Schnoegl, Sigrid, Suenkel, Christin, Schneider, Luisa-Sophie, Rybak-Wolf, Agnieszka, Kochnowsky, Bianca, Byrne, Lauren M., Wild, Edward J., Nielsen, Jørgen E., Dittmar, Gunnar, Peters, Oliver, Beule, Dieter, and Wanker, Erich E.

Published
2023
Full Text
View/download PDF

4. Serum IL-6, sAXL, and YKL-40 as systemic correlates of reduced brain structure and function in Alzheimer’s disease: results from the DELCODE study

Author

Brosseron, Frederic, Maass, Anne, Kleineidam, Luca, Ravichandran, Kishore Aravind, Kolbe, Carl-Christian, Wolfsgruber, Steffen, Santarelli, Francesco, Häsler, Lisa M., McManus, Róisín, Ising, Christina, Röske, Sandra, Peters, Oliver, Cosma, Nicoleta-Carmen, Schneider, Luisa-Sophie, Wang, Xiao, Priller, Josef, Spruth, Eike J., Altenstein, Slawek, Schneider, Anja, Fliessbach, Klaus, Wiltfang, Jens, Schott, Björn H., Buerger, Katharina, Janowitz, Daniel, Dichgans, Martin, Perneczky, Robert, Rauchmann, Boris-Stephan, Teipel, Stefan, Kilimann, Ingo, Görß, Doreen, Laske, Christoph, Munk, Matthias H., Düzel, Emrah, Yakupow, Renat, Dobisch, Laura, Metzger, Coraline D., Glanz, Wenzel, Ewers, Michael, Dechent, Peter, Haynes, John Dylan, Scheffler, Klaus, Roy, Nina, Rostamzadeh, Ayda, Spottke, Annika, Ramirez, Alfredo, Mengel, David, Synofzik, Matthis, Jucker, Mathias, Latz, Eicke, Jessen, Frank, Wagner, Michael, and Heneka, Michael T.

Published
2023
Full Text
View/download PDF

5. Arterial hypertension and β-amyloid accumulation have spatially overlapping effects on posterior white matter hyperintensity volume: a cross-sectional study

Author

Bernal, Jose, Schreiber, Stefanie, Menze, Inga, Ostendorf, Anna, Pfister, Malte, Geisendörfer, Jonas, Nemali, Aditya, Maass, Anne, Yakupov, Renat, Peters, Oliver, Preis, Lukas, Schneider, Luisa, Herrera, Ana Lucia, Priller, Josef, Spruth, Eike Jakob, Altenstein, Slawek, Schneider, Anja, Fliessbach, Klaus, Wiltfang, Jens, Schott, Björn H., Rostamzadeh, Ayda, Glanz, Wenzel, Buerger, Katharina, Janowitz, Daniel, Ewers, Michael, Perneczky, Robert, Rauchmann, Boris-Stephan, Teipel, Stefan, Kilimann, Ingo, Laske, Christoph, Munk, Matthias H., Spottke, Annika, Roy, Nina, Dobisch, Laura, Dechent, Peter, Scheffler, Klaus, Hetzer, Stefan, Wolfsgruber, Steffen, Kleineidam, Luca, Schmid, Matthias, Berger, Moritz, Jessen, Frank, Wirth, Miranka, Düzel, Emrah, and Ziegler, Gabriel

Published
2023
Full Text
View/download PDF

6. Exploring the ATN classification system using brain morphology

Author

Heinzinger, Nils, Maass, Anne, Berron, David, Yakupov, Renat, Peters, Oliver, Fiebach, Jochen, Villringer, Kersten, Preis, Lukas, Priller, Josef, Spruth, Eike Jacob, Altenstein, Slawek, Schneider, Anja, Fliessbach, Klaus, Wiltfang, Jens, Bartels, Claudia, Jessen, Frank, Maier, Franziska, Glanz, Wenzel, Buerger, Katharina, Janowitz, Daniel, Perneczky, Robert, Rauchmann, Boris-Stephan, Teipel, Stefan, Killimann, Ingo, Göerß, Doreen, Laske, Christoph, Munk, Matthias H., Spottke, Annika, Roy, Nina, Heneka, Michael T., Brosseron, Frederic, Dobisch, Laura, Ewers, Michael, Dechent, Peter, Haynes, John Dylan, Scheffler, Klaus, Wolfsgruber, Steffen, Kleineidam, Luca, Schmid, Matthias, Berger, Moritz, Düzel, Emrah, and Ziegler, Gabriel

Published
2023
Full Text
View/download PDF

7. Brain reserve contributes to distinguishing preclinical Alzheimer’s stages 1 and 2

Author

Yildirim, Zerrin, Delen, Firuze, Berron, David, Baumeister, Hannah, Ziegler, Gabriel, Schütze, Hartmut, Glanz, Wenzel, Dobisch, Laura, Peters, Oliver, Freiesleben, Silka Dawn, Schneider, Luisa-Sophie, Priller, Josef, Spruth, Eike Jakob, Schneider, Anja, Fliessbach, Klaus, Wiltfang, Jens, Schott, Björn-Hendrik, Meiberth, Dix, Buerger, Katharina, Janowitz, Daniel, Perneczky, Robert, Rauchmann, Boris-Stephan, Teipel, Stefan, Kilimann, Ingo, Laske, Christoph, Munk, Matthias H., Spottke, Annika, Roy, Nina, Heneka, Michael, Brosseron, Frederic, Wagner, Michael, Roeske, Sandra, Ramirez, Alfredo, Ewers, Michael, Dechent, Peter, Hetzer, Stefan, Scheffler, Klaus, Kleineidam, Luca, Wolfsgruber, Steffen, Yakupov, Renat, Schmid, Matthias, Berger, Moritz, Gurvit, Hakan, Jessen, Frank, and Duzel, Emrah

Published
2023
Full Text
View/download PDF

8. Improving 3D convolutional neural network comprehensibility via interactive visualization of relevance maps: evaluation in Alzheimer’s disease

Author

Dyrba, Martin, Hanzig, Moritz, Altenstein, Slawek, Bader, Sebastian, Ballarini, Tommaso, Brosseron, Frederic, Buerger, Katharina, Cantré, Daniel, Dechent, Peter, Dobisch, Laura, Düzel, Emrah, Ewers, Michael, Fliessbach, Klaus, Glanz, Wenzel, Haynes, John-Dylan, Heneka, Michael T., Janowitz, Daniel, Keles, Deniz B., Kilimann, Ingo, Laske, Christoph, Maier, Franziska, Metzger, Coraline D., Munk, Matthias H., Perneczky, Robert, Peters, Oliver, Preis, Lukas, Priller, Josef, Rauchmann, Boris, Roy, Nina, Scheffler, Klaus, Schneider, Anja, Schott, Björn H., Spottke, Annika, Spruth, Eike J., Weber, Marc-André, Ertl-Wagner, Birgit, Wagner, Michael, Wiltfang, Jens, Jessen, Frank, and Teipel, Stefan J.

Published
2021
Full Text
View/download PDF

10. Cognitive behavioural therapy for the treatment of late life depression: study protocol of a multicentre, randomized, observer-blinded, controlled trial (CBTlate)

Author

Dafsari, Forugh S., Bewernick, Bettina, Biewer, Matthias, Christ, Hildegard, Domschke, Katharina, Froelich, Lutz, Hellmich, Martin, Luppa, Melanie, Peters, Oliver, Ramirez, Alfredo, Riedel-Heller, Steffi, Schramm, Elisabeth, Vry, Magnus-Sebastian, Wagner, Michael, Hautzinger, Martin, and Jessen, Frank

Published
2019
Full Text
View/download PDF

11. Prevalence of abnormal Alzheimer’s disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples

Author

Wolfsgruber, Steffen, Molinuevo, José Luis, Wagner, Michael, Teunissen, Charlotte E., Rami, Lorena, Coll-Padrós, Nina, Bouwman, Femke H., Slot, Rosalinde E. R., Wesselman, Linda M. P., Peters, Oliver, Luther, Katja, Buerger, Katharina, Priller, Josef, Laske, Christoph, Teipel, Stefan, Spottke, Annika, Heneka, Michael T., Düzel, Emrah, Drzezga, Alexander, Wiltfang, Jens, Sikkes, Sietske A. M., van der Flier, Wiesje M., Jessen, Frank, and on behalf of the Euro-SCD working group

Published
2019
Full Text
View/download PDF

12. Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study

Author

Miebach, Lisa, Wolfsgruber, Steffen, Polcher, Alexandra, Peters, Oliver, Menne, Felix, Luther, Katja, Incesoy, Enise, Priller, Josef, Spruth, Eike, Altenstein, Slawek, Buerger, Katharina, Catak, Cihan, Janowitz, Daniel, Perneczky, Robert, Utecht, Julia, Laske, Christoph, Buchmann, Martina, Schneider, Anja, Fliessbach, Klaus, Kalbhen, Pascal, Heneka, Michael T., Brosseron, Frederic, Spottke, Annika, Roy, Nina, Teipel, Stefan J., Kilimann, Ingo, Wiltfang, Jens, Bartels, Claudia, Düzel, Emrah, Dobisch, Laura, Metzger, Coraline, Meiberth, Dix, Ramirez, Alfredo, Jessen, Frank, and Wagner, Michael

Published
2019
Full Text
View/download PDF

13. Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project

Author

van Maurik, Ingrid S., Slot, Rosalinde E. R., Verfaillie, Sander C. J., Zwan, Marissa D., Bouwman, Femke H., Prins, Niels D., Teunissen, Charlotte E., Scheltens, Philip, Barkhof, Frederik, Wattjes, Mike P., Molinuevo, Jose Luis, Rami, Lorena, Wolfsgruber, Steffen, Peters, Oliver, Jessen, Frank, Berkhof, Johannes, van der Flier, Wiesje M., and for the Alzheimer’s Disease Neuroimaging Initiative

Published
2019
Full Text
View/download PDF

14. Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkers—results from the DELCODE study

Author

Sannemann, Lena, Schild, Ann-Katrin, Altenstein, Slawek, Bartels, Claudia, Brosseron, Frederic, Buerger, Katharina, Cosma, Nicoleta-Carmen, Fliessbach, Klaus, Freiesleben, Silka Dawn, Glanz, Wenzel, Heneka, Michael T., Janowitz, Daniel, Kilimann, Ingo, Kobeleva, Xenia, Laske, Christoph, Metzger, Coraline D., Munk, Matthias H. J., Perneczky, Robert, Peters, Oliver, Polcher, Alexandra, Priller, Josef, Rauchmann, Boris-Stephan, Rösch, Christina, Rudolph, Janna, Schneider, Anja, Spottke, Annika, Spruth, Eike Jakob, Teipel, Stefan J., Vukovich, Ruth, Wagner, Michael, Wiltfang, Jens, Wolfsgruber, Steffen, Duezel, Emrah, Jessen, Frank, Sannemann, Lena, Schild, Ann-Katrin, Altenstein, Slawek, Bartels, Claudia, Brosseron, Frederic, Buerger, Katharina, Cosma, Nicoleta-Carmen, Fliessbach, Klaus, Freiesleben, Silka Dawn, Glanz, Wenzel, Heneka, Michael T., Janowitz, Daniel, Kilimann, Ingo, Kobeleva, Xenia, Laske, Christoph, Metzger, Coraline D., Munk, Matthias H. J., Perneczky, Robert, Peters, Oliver, Polcher, Alexandra, Priller, Josef, Rauchmann, Boris-Stephan, Rösch, Christina, Rudolph, Janna, Schneider, Anja, Spottke, Annika, Spruth, Eike Jakob, Teipel, Stefan J., Vukovich, Ruth, Wagner, Michael, Wiltfang, Jens, Wolfsgruber, Steffen, Duezel, Emrah, and Jessen, Frank

Published
2020

15. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer’s dementia

Author

Frölich, Lutz, Peters, Oliver, Lewczuk, Piotr, Gruber, Oliver, Teipel, Stefan J., Gertz, Hermann J., Jahn, Holger, Jessen, Frank, Kurz, Alexander, Luckhaus, Christian, Hüll, Michael, Pantel, Johannes, Reischies, Friedel M., Schröder, Johannes, Wagner, Michael, Rienhoff, Otto, Wolf, Stefanie, Bauer, Chris, Schuchhardt, Johannes, Heuser, Isabella, Rüther, Eckart, Henn, Fritz, Maier, Wolfgang, Wiltfang, Jens, and Kornhuber, Johannes

Subjects
Male, BMI, COMT Val108/158Met polymorphism, DBH-1021C/T polymorphism, Hemoglobin A1c (HbA1c), Insulin detemir, Type 2 diabetes mellitus, physiopathology [Cognitive Dysfunction], Support Vector Machine, endocrine system diseases, pathology [Cognitive Dysfunction], cerebrospinal fluid [Amyloid beta-Peptides], Neuropsychological Tests, Hippocampus, lcsh:RC346-429, pathology [Alzheimer Disease], 610 Medical sciences Medicine, Medizinische Fakultät, Phospho-tau, Amyloid-beta 42, Phosphorylation, diagnostic imaging [Hippocampus], diagnosis [Alzheimer Disease], Organ Size, Prognosis, amyloid beta-protein (1-42), cerebrospinal fluid [Biomarkers], Disease Progression, Educational Status, Female, Alzheimer’s dementia, MAPT protein, human, tau Proteins, physiopathology [Alzheimer Disease], Sensitivity and Specificity, lcsh:RC321-571, Alzheimer Disease, mental disorders, Humans, Cognitive Dysfunction, cerebrospinal fluid [Peptide Fragments], ddc:610, lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry, lcsh:Neurology. Diseases of the nervous system, Aged, Amyloid beta-Peptides, Research, Mild cognitive impairment, amyloid beta-protein (1-40), Hippocampal volume, Peptide Fragments, pathology [Hippocampus], diagnosis [Cognitive Dysfunction], cerebrospinal fluid [tau Proteins], Tau, Prediction, Biomarkers, Follow-Up Studies
Abstract

Background The progression of mild cognitive impairment (MCI) to Alzheimer’s disease (AD) dementia can be predicted by cognitive, neuroimaging, and cerebrospinal fluid (CSF) markers. Since most biomarkers reveal complementary information, a combination of biomarkers may increase the predictive power. We investigated which combination of the Mini-Mental State Examination (MMSE), Clinical Dementia Rating (CDR)-sum-of-boxes, the word list delayed free recall from the Consortium to Establish a Registry of Dementia (CERAD) test battery, hippocampal volume (HCV), amyloid-beta1–42 (Aβ42), amyloid-beta1–40 (Aβ40) levels, the ratio of Aβ42/Aβ40, phosphorylated tau, and total tau (t-Tau) levels in the CSF best predicted a short-term conversion from MCI to AD dementia. Methods We used 115 complete datasets from MCI patients of the “Dementia Competence Network”, a German multicenter cohort study with annual follow-up up to 3 years. MCI was broadly defined to include amnestic and nonamnestic syndromes. Variables known to predict progression in MCI patients were selected a priori. Nine individual predictors were compared by receiver operating characteristic (ROC) curve analysis. ROC curves of the five best two-, three-, and four-parameter combinations were analyzed for significant superiority by a bootstrapping wrapper around a support vector machine with linear kernel. The incremental value of combinations was tested for statistical significance by comparing the specificities of the different classifiers at a given sensitivity of 85%. Results Out of 115 subjects, 28 (24.3%) with MCI progressed to AD dementia within a mean follow-up period of 25.5 months. At baseline, MCI-AD patients were no different from stable MCI in age and gender distribution, but had lower educational attainment. All single biomarkers were significantly different between the two groups at baseline. ROC curves of the individual predictors gave areas under the curve (AUC) between 0.66 and 0.77, and all single predictors were statistically superior to Aβ40. The AUC of the two-parameter combinations ranged from 0.77 to 0.81. The three-parameter combinations ranged from AUC 0.80–0.83, and the four-parameter combination from AUC 0.81–0.82. None of the predictor combinations was significantly superior to the two best single predictors (HCV and t-Tau). When maximizing the AUC differences by fixing sensitivity at 85%, the two- to four-parameter combinations were superior to HCV alone. Conclusion A combination of two biomarkers of neurodegeneration (e.g., HCV and t-Tau) is not superior over the single parameters in identifying patients with MCI who are most likely to progress to AD dementia, although there is a gradual increase in the statistical measures across increasing biomarker combinations. This may have implications for clinical diagnosis and for selecting subjects for participation in clinical trials.

Published
2017

16. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE).

Author

Jessen, Frank, Spottke, Annika, Boecker, Henning, Brosseron, Frederic, Buerger, Katharina, Catak, Cihan, Fliessbach, Klaus, Franke, Christiana, Fuentes, Manuel, Heneka, Michael T., Janowitz, Daniel, Kilimann, Ingo, Laske, Christoph, Menne, Felix, Nestor, Peter, Peters, Oliver, Priller, Josef, Pross, Verena, Ramirez, Alfredo, and Schneider, Anja

Subjects
ALZHEIMER'S patients, COGNITION disorders, DEMENTIA, APOLIPOPROTEIN E, CEREBROSPINAL fluid, POSITRON emission tomography, MAGNETIC resonance imaging
Abstract

Background: Deep phenotyping and longitudinal assessment of predementia at-risk states of Alzheimer's disease (AD) are required to define populations and outcomes for dementia prevention trials. Subjective cognitive decline (SCD) is a pre-mild cognitive impairment (pre-MCI) at-risk state of dementia, which emerges as a highly promising target for AD prevention. Methods: The German Center for Neurodegenerative Diseases (DZNE) is conducting the multicenter DZNE-Longitudinal Cognitive Impairment and Dementia Study (DELCODE), which focuses on the characterization of SCD in patients recruited from memory clinics. In addition, individuals with amnestic MCI, mild Alzheimer's dementia patients, first-degree relatives of patients with Alzheimer's dementia and cognitively unimpaired control subjects are studied. The total number of subjects to be enrolled is 1000. Participants receive extensive clinical and neuropsychological assessments, magnetic resonance imaging, positron emission tomography and biomaterial collection is perfomed. In this publication, we report cognitive and clinical data as well as apolipoprotein E (APOE) genotype and cerebrospinal fluid (CSF) biomarker results of the first 394 baseline data sets. Results: In comparison with the control group, patients with SCD showed slightly poorer performance on cognitive and functional measures (Alzheimer's Disease Assessment Scale-cognitive part, Clinical Dementia Rating, Functional Activities Questionnaire), with all mean scores in a range which would be considered unimpaired. APOE4 genotype was enriched in the SCD group in comparison to what would be expected in the population and the frequency was significantly higher in comparison to the control group. CSF Aβ42 was lower in the SCD group in comparison to the control group at a statistical trend with age as a covariate. There were no group differences in Tau or pTau concentrations between the SCD and the control groups. The differences in all measures between the MCI group and the AD group were as expected. Conclusions: The initial baseline data for DELCODE support the approach of using SCD in patients recruited through memory clinics as an enrichment strategy for late-stage preclinical AD. This is indicated by slightly lower performance in a range of measures in SCD in comparison to the control subjects as well as by enriched APOE4 frequency and lower CSF Aβ42 concentration. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

17. Apolipoprotein E-dependent load of white matter hyperintensities in Alzheimer's disease: a voxel-based lesion mapping study.

Author

Morgen, Katrin, Schneider, Michael, Frölich, Lutz, Tost, Heike, Plichta, Michael M., Kölsch, Heike, Rakebrandt, Fabian, Rienhoff, Otto, Jessen, Frank, Peters, Oliver, Jahn, Holger, Luckhaus, Christian, Hüll, Michael, Gertz, Hermann-Josef, Schröder, Johannes, Hampel, Harald, Teipel, Stefan J., Pantel, Johannes, Heuser, Isabella, and Wiltfang, Jens

Subjects
ALZHEIMER'S disease diagnosis, ALZHEIMER'S disease, WHITE matter (Nerve tissue), APOLIPOPROTEIN E, GENE mapping, COGNITIVE ability, DISEASE prevalence, MAGNETIC resonance imaging
Abstract

Introduction: White matter (WM) magnetic resonance imaging (MRI) hyperintensities are common in Alzheimer's disease (AD), but their pathophysiological relevance and relationship to genetic factors are unclear. In the present study, we investigated potential apolipoprotein E (APOE)-dependent effects on the extent and cognitive impact of WM hyperintensities in patients with AD. Methods: WM hyperintensity volume on fluid-attenuated inversion recovery images of 201 patients with AD (128 carriers and 73 non-carriers of the APOE Ɛ4 risk allele) was determined globally as well as regionally with voxelbased lesion mapping. Clinical, neuropsychological and MRI data were collected from prospective multicenter trials conducted by the German Dementia Competence Network. Results: WM hyperintensity volume was significantly greater in non-carriers of the APOE Ɛ4 allele. Lesion distribution was similar among Ɛ4 carriers and non-carriers. Only Ɛ4 non-carriers showed a correlation between lesion volume and cognitive performance. Conclusion: The current findings indicate an increased prevalence of WM hyperintensities in non-carriers compared with carriers of the APOE Ɛ4 allele among patients with AD. This is consistent with a possibly more pronounced contribution of heterogeneous vascular risk factors to WM damage and cognitive impairment in patients with AD without APOE Ɛ4-mediated risk. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

18. Beyond surgery: clinical and economic impact of Enhanced Recovery After Surgery programs.

Author

Joliat, Gaëtan-Romain, Ljungqvist, Olle, Wasylak, Tracy, Peters, Oliver, and Demartines, Nicolas

Subjects
ECONOMIC impact, PERIOPERATIVE care
Abstract

Background: Enhanced Recovery After Surgery (ERAS) is a perioperative management based on multimodality and multidisciplinary work. ERAS has been shown to have important clinical and economic benefits, but its spread remains slow worldwide.Discussion: This manuscript reviews the overall program benefits and focuses on important aspects for implementation well beyond surgery. Implementation of ERAS pathways improves clinical outcomes and induces substantial economic gains. ERAS is the current surgical revolution. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results